Hepatitis C is the biggest reason for liver transplants in the United States and it is estimated that three million Americans are infected with the virus.
Now a promising study is showing a trio of oral medicines produced unprecedented cure rates in patients who failed to benefit from standard treatment.
The study also showed a very high cure rate for newly treated patients.
The results were released at an annual meeting of the American Association for the Study of Liver Disease.
In the current study, some 93 percent of patients who failed prior therapy were cured after 12 weeks of taking the new drugs.
Scientists say nobody anywhere has broken the 50 percent mark in cure rates for this population.
A new, more involved study is now planned.
